PharmTech Weekly Roundup–March 6, 2026

Welcome back to the PharmTech Weekly Roundup! I’m Susan Haigney, lead editor of PharmTech.

There were some strategic investments made by industry this week, and FDA called out misleading claims about GLP-1s. Be sure to check out the full articles on PharmTech.com.

Developments across the sector highlight a period of rapid acceleration and structural modernization. A few themes our editors saw this week include the use of AI and regulatory incentives to compress development and review timelines; a wave of capital investment aimed at bolstering regional supply chain resilience; and a move toward continuous, data-driven monitoring to replace traditional, reactive quality control measures.

GLP-1s continue to dominate the headlines. FDA initiated proactive enforcement this week by issuing 30 warning letters to telehealth sites for misleading "sameness" claims regarding unapproved compounded GLP-1 drugs. This action is the second significant enforcement wave since the agency's broad crackdown on direct-to-consumer advertising began in September 2025.

In Europe, Novo Nordisk is investing €432 million to retrofit a facility in Ireland for high-volume oral GLP-1 production, complemented by an AI-driven partnership with Vivtex to optimize intestinal absorption for oral biologics.

Norgine has committed a total of $67 million to modernize its Wales manufacturing facility, focusing on high-speed, energy-efficient processes and regional supply resilience for the UK and European markets.

In drug development news, FDA granted accelerated approval for Boehringer’s Hernexeos (zongertinib) as a first-line HER2-mutant non-small cell lung cancer treatment in just 44 days, utilizing the National Priority Voucher Program to reward manufacturing domestication and the addressing of unmet health needs.

Sartorius’ new genome-edited CHO host cell line triples productivity and reduces cell line development timelines to as little as nine weeks while maintaining the long-term genetic stability required for commercial scale-up.

This week, PharmTech also looked at how the industry is using AI and other technologies to increase efficiency.

AI is transforming the industry by cutting discovery and manufacturing cycle times by up to 40% through real-time "continuous learning loops" between physical labs and computational models.

And author Tony Cundell provided an overview on how analytical techniques are used in aseptic processing. He explains that, to reduce costly product rejections, the industry is transitioning from periodic to continuous, PAT-oriented monitoring that uses real-time sensors and multivariate statistical control to detect anomalies instantly.

These updates underscore a shift where efficiency and resilience are no longer just goals, but regulatory and competitive requirements. Staying ahead requires integrating advanced analytical tools and strategic infrastructure upgrades into the standard manufacturing lifecycle.